Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cullinan Apollo
Cambridge, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Cullinan Apollo was a subsidiary of Cullinan Oncology (now Cullinan Therapeutics) established to develop VK-2019, an oral small molecule EBNA1 inhibitor for EBV-driven cancers. Despite promising preclinical results, clinical efficacy was not demonstrated and the program was terminated, leading to the inactivation of Cullinan Apollo as a development entity.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
The Wistar Institute
Beyond the preview
Go deeper on Cullinan Apollo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cullinan Apollo.